Citi Pharma 1QFY27 profit rises 22% to Rs249m

Citi Pharma Ltd (CPHL) recorded consolidated earnings of Rs248.79 million in the quarter ending September 30, 2026, up 22.14% from a year earlier, Mettis Global reported. Basic and diluted earnings per share reached Rs1.09, compared with Rs0.89 in the corresponding quarter of 2025. Revenue advanced 4.28% to Rs3.51 billion, while the cost of sales was slightly lower at Rs2.84 billion.

A 29.92% increase in gross profit to Rs674.26 million supported operating profit, which rose 21.60% to Rs511.16 million. Financial charges eased 16.93% to Rs100.67 million, but marketing and distribution costs more than doubled to Rs107.79 million, while income tax climbed 46.47% to Rs144.40 million. Other income also fell 45.14% to Rs15.78 million, limiting the increase in final earnings relative to the rise in pre-tax profit, which reached Rs393.19 million, 30.08% higher year on year.